NEOG
Neogen Corporation
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$11.83
+1.63%Year over year
Reported trailing growth
- Revenue
- -2.7%
- EBITDA
- +118.3%
- EBIT
- —
- EPS
- +99.3%
- Free cash flow
- +168.8%
- Operating cash flow
- +42.8%
Forward estimates
Based on analyst estimates
- Revenue
- -0.7%
- EBITDA
- +38.9%
- EPS
- +712.4%
Three-year CAGR
- Revenue
- +1.9%
- EBITDA
- +11.7%
- EBIT
- —
- Net income
- +99.3%
- EPS
- +99.2%
- Free cash flow
- +168.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of May 1, 2026